) provided partial protection but failed to predict protection. Neutralizing antibody titers between 500 and 800 provided partial protection, while titers higher than 1,000 conferred protection. In conclusion, this study emphasizes that regardless of the immunization regimen or the time of challenge, neutralizing antibody titers are better predictors of protection than total anti-PA titers.
The virulence of Bacillus anthracis, the causative agent of anthrax, is attributed to the anthrax tripartite toxin (composed of protective antigen [PA] , lethal factor [LF] , and edema factor) and its capsule. Toxic activity is expressed only when PA is combined with LF and with edema factor, forming the lethal toxin and edema toxin, respectively (2, 11) . Consistent with the central role of PA in anthrax toxin action, preexposure vaccination with PA-based vaccines induces protective immunity to anthrax (4) .
The protective efficacy of PA-based vaccines against the onset of fatal disease following challenge with B. anthracis spores varies in different animal models. For example, anthrax vaccine adsorbed (AVA), the human vaccine licensed in the United States, fails to protect mice (17) , only partially protects guinea pigs from challenge with several B. anthracis isolates (3, 9) , and is highly efficacious in rabbits and rhesus monkeys (3) . Although the rhesus monkey model has been suggested as the best model for human disease, the rabbit model has lately gained acceptance as an appropriate model for evaluation of the anti-anthrax vaccines (8, 12, 13, 18) .
Studies with rabbits vaccinated with either AVA or recombinant PA-based vaccines (8, 13) revealed that quantitative anti-PA immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody titers could be used as serological correlates for protection against challenge by the aerosol route with Ames spores.
In a previous study (16) we demonstrated that in PA-vaccinated guinea pigs, neutralizing antibody titers could predict protection against intradermal challenge with Vollum spores.
Here, we demonstrated the efficacy of a PA-based vaccine to prevent the onset of inhalation anthrax in rabbits challenged intranasally with either Vollum or ATCC 6605 spores and found that neutralizing antibody titers are better serological correlates than anti-PA titers for efficient protection.
MATERIALS AND METHODS
B. anthracis strains. The virulent strains used in this study were ATCC 14578 (Vollum) (Tox ϩ Cap ϩ ) and ATCC 6605 (Tox ϩ Cap ϩ ) from the IIBR collection (1, 6) . The intranasal 50% lethal dose (LD 50 ) for each strain in rabbits was estimated by using three inoculum doses (three animals per group) and a refinement experiment with three intermediate doses (three animals per group). The ATCC 14578 and ATCC 6605 LD 50 s were then calculated by the method of Reed and Muench (15) , and the estimated doses were 3 ϫ 10 5 and 2 ϫ 10 4 spores, respectively, as determined by direct plate counting. The strain used for PA vaccine preparation was strain ATCC 14185 (Tox ϩ Cap Ϫ ) from the IIBR collection (6, 16) .
Animals. New Zealand White rabbits (2.5 to 3.5 kg) were obtained from Harlan (Israel). The animals received food and water ad libitum. All animals were cared for according to the 1997 NIH guidelines for the care and use of laboratory animals; the IIBR animal use committee approved all experimental protocols.
Vaccination and challenge. Purified PA isolated from strain ATCC 14185 was absorbed to Alhydrogel (Superfos Biosector) to generate a 50-g/ml PA vaccine dose, as previously described (16) . The animals were vaccinated by intramuscular injection of 0.5 ml of the PA-based vaccine. The immunization regimens are shown in Table 1 . Different concentrations of PA-based vaccines were generated by dilution of the original vaccine in phosphate-buffered saline (PBS). Serum samples were collected biweekly, and antibody titers were determined by ELISA and cytotoxicity neutralization assays. Prior to challenge, the rabbits were anesthetized by subcutaneous injection of a mixture of ketamine HCl (40 mg/kg of body weight) and xylazine (5 mg/kg). The animals were challenged intranasally by unilateral instillation of either Vollum or ATCC 6605 spores (0.5 ml per nostril). Survival was recorded for 30 days after challenge.
ELISA for total anti-PA titers. Antibody titers were determined by direct ELISA in 96-well microtiter plates (Nunc, Rosklide, Denmark), using purified PA (16) as the capture antigen and an alkaline phosphatase-conjugated goat anti-rabbit IgG (Sigma, St. Louis, MO) as the detection reagent. The plates were coated with 10 g/ml of purified PA (1 g/well) in NaHCO 3 buffer (50 mM, pH 9.6) and subsequently blocked with 5% skim milk (Becton Dickinson, Sparks, MD). The sera tested and the internal positive and negative controls were serially diluted in twofold steps, and the plates were then incubated for 1 h at 37°C. The plates were washed with PBS containing 0.05% Tween 20 and were developed with detecting antibody conjugate, with p-nitrophenyl phosphate (Sigma, St. Louis, MO) as the substrate. Absorbance at 405 nm was determined using a Spectramax 190 microplate reader (Molecular Devices, Sunnyvale, CA). The end point was defined as the highest dilution at which the absorbance was Ͼ3 standard deviations above that of the negative control (normal rabbit serum). Antibody titers were expressed as reciprocal end point dilutions.
Determination of cytotoxicity neutralization titers. Neutralizing antibody titers were determined by assessment of the ability to prevent the death of murine macrophage J774.1 cells induced by the PA/LF toxin complex. The cytotoxicity assays were performed as described previously (10, 16) . Antibody titers were expressed as reciprocals of the end point dilutions.
Passive immunization. Immune serum was collected (between weeks 6 and 10) from rabbits immunized with two injections (at zero time and 4 weeks) of the PA-based vaccine. Various doses of the immune serum were administered intramuscularly to naïve rabbits. Two days after serum administration, rabbits were bled for estimation of neutralizing antibodies prior to intranasal spore instillation.
Statistical analysis. The association of survival and the logarithm of neutralizing or total anti-PA titers was tested by an unpaired two-tailed t test. The correlation between neutralizing antibodies and total anti-PA was tested by linear regression. All tests were performed using GraphPad Prism, version 4.03 for Windows (GraphPad Software, San Diego, CA; www.graphpad.com). The hypothetical antibody titer that conferred protection to 50% of the immunized rabbits (hPT 50 ) was calculated by adapting the Reed-Muench method for determination of LD 50 (15) . For the actual calculation, we used the dilutions of serum (ELISA or neutralizing titers) and the percentage of survivors (instead of the percentage of dead animals).
RESULTS
Evaluation of immunization regimen. In order to determine the optimal rabbit immunization regimen, using a PA-based vaccine, we examined the abilities of different regimens to induce anti-PA antibodies (defined by ELISA) and neutralizing antibodies (defined by inhibition of the lethal toxin effect in a cytotoxicity assay). As shown in Table 1 , two injections that were 4 weeks apart generated the most efficient antibody response, which peaked between 6 and 10 weeks after the first injection (titers for total anti-PA and neutralizing antibodies, 724,000 and 18,000, respectively) and then gradually declined. Other vaccination regimens that included one injection ( Table  1 , group 1), two injections that were 2 weeks apart ( Table 1 , group 2), and two injections that were 13 weeks apart (Table 1 , group 5) resulted in lower antibody responses (P Ͻ 0.01 compared to group 3). Three injections that were 2 weeks apart ( Table 1 , group 4) induced titers that did not differ significantly from group 3 titers (P Ͼ 0.05). The regimen consisting of two injections that were 4 weeks apart seemed to be optimal since addition of a third boost at week 13 (Table 1 , group 6) resulted in titers of specific anti-PA antibodies that were similar to but not greater than those at week 6.
Protection conferred by PA-based vaccine. The protection conferred by the optimal immunization regimen described above was tested by intranasal challenges with spores of two virulent strains, strains Vollum and ATCC 6605. The prechallenge immune status of the animals at week 10 after initiation of vaccination and the challenge parameters are shown in Table 2 . The PA-based vaccine conferred full protection against both strains (eight of eight animals in each group) when the animals were tested with various doses ranging from 26 to 2,300 LD 50 s. In addition, no changes in the anti-PA antibody titers (both total and neutralizing) were detected within 30 days after challenge (data not shown), indicating that the animals were highly immunized against PA, which probably prevented bacterial growth.
Correlates for protection. To define a serological marker that could predict protection, two experimental approaches were used: active immunizations and pretreatment with specific anti-PA antibodies. We determined the protection conferred by immunization with decreasing amounts of PA-based vaccine in the regimen selected, using undiluted or PBS-diluted PAbased vaccine. Ten weeks after the first injection, the animals were challenged by intranasal instillation of 300 LD 50 s of ei- 
a Rabbits were immunized with PA-based vaccine (0.5 ml, 50 g/ml). b GMT, geometric mean titer. c The induction ratio was calculated with respect to group 1 (single immunization at day 0). The total anti-PA and neutralizing antibody titers were determined by ELISA and J774.1 cytotoxicity assays, respectively. a Animals were vaccinated with PA-based vaccine (0.5 ml, 50 g/ml) by two immunizations that were 4 weeks apart. GMT, geometric mean titer. b The animals were challenged at week 10 after immunization by intranasal spore instillation. Nonimmunized animals (n ϭ 4 for each strain) died within 2 to 3 days after infection.
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ther Vollum or ATCC 6605 spores. The prechallenge immune response (neutralizing antibody and total anti-PA antibody titers) and protection efficiency were determined (Fig. 1) . All the rabbits that were immunized with undiluted vaccine (25 g PA) or with PA-based vaccine diluted 1:4 (ϳ6.25 g PA) survived. Further dilution of the PA-based vaccine resulted in decreasing titers of anti-PA and neutralizing antibodies along with partial protection. Neutralizing antibody titers higher than 1,000 conferred protection to 14/16 rabbits (Fig. 1A) . Total anti-PA titers higher than 100,000 conferred protection to 7/7 rabbits, and titers between 10 4 and 10 5 protected 8/11 rabbits (Fig. 1B) . We assessed the level of protection conferred with greater intervals between the last vaccination and challenge. Rabbits that were immunized using six immunization regimens (Table 1) were monitored up to weeks 19 and 23 after initiation of immunization and then challenged with 10 and 160 LD 50 s of Vollum spores, respectively ( Table 3 ).
The prechallenge PA-specific antibody levels, survival rates, and mean times to death are shown in Table 3 . Full protection was conferred when there was a 6-week interval between the last vaccination and challenge (groups 5 and 6) and when there was a 15-week interval (group 3); all the other immunization regimens (15-, 19-, and 23-week intervals) conferred partial protection with a marked delay in the mean time to death ( Table 3 ). The individual total anti-PA and neutralizing antibody titers were plotted against protective ability (Fig. 2 ). The data demonstrate that neutralizing antibody titers higher than 1,000 conferred full protection (P Ͻ 0.001) (Fig. 2A) . Total anti-PA antibody titers higher than 100,000 conferred protection (P Ͻ 0.001), whereas lower titers (between 10 4 and 10 5 ) provided partial protection but failed to predict protection (P ϭ 0.2929) (Fig. 2B) .
The data from the active immunization experiments (Tables 1  and 2 and Fig. 1 and 2 ) were analyzed to determine the hypo- FIG. 1 . Relationship between antibody titer of rabbits immunized with PA-based vaccine and survival upon challenge via intranasal spore instillation. Rabbits were immunized with either undiluted or PBS-diluted vaccines by two immunizations that were 4 weeks apart, and at week 10 their neutralizing (A) and total anti-PA (␣-PA) (B) antibody titers were determined. The rabbits were then challenged with 300 LD 50 s of either Vollum (circles) (n ϭ 12) or ATCC 6605 (triangles) (n ϭ 13). Solid and open symbols represent surviving and dead animals, respectively. GMT, geometric mean titer. b GMT, geometric mean titer. c The mean time to death (MTTD) was determined by determining the average time to death for each group, excluding the survivors. d BDL, below the detection limit.
thetical antibody titers (15) that conferred protection to 50% of the immunized rabbits. The calculated hPT 50 s obtained were 940 for neutralizing antibodies and 25,000 for total anti-PA antibodies. These hPT 50 s were then used as central axes to analyze the relationship between neutralizing or total anti-PA titers and survival (Fig. 3) . Most of the animals that developed antibody titers higher than the calculated hPT 50 were protected against challenge (37/39 survivors [94.5%]) (Fig. 3 , upper right quadrant). Animals with antibody titers that were lower than the calculated hPT 50 were not protected (5/17 survivors [29.4%]) (Fig. 3 , lower left quadrant). According to the neutralizing antibody titer criteria, titers higher than the hPT 50 indicated survival of 37 of 39 animals (ϳ94.5%). All the animals that qualified for the neutralizing hPT 50 criteria also qualified for the total anti-PA hPT 50 criteria. On the other hand, total anti-PA titers higher than the calculated hPT 50 indicated that 39 of 48 animals (ϳ81.2%) survived. Of the nine animals that qualified for the total anti-PA hPT 50 criteria but failed to qualify for the neutralizing hPT 50 criteria, only two survived (ϳ22.2%) (Fig. 3 , lower right quadrant). Although there is a good correlation between neutralizing and total anti-PA titers (r 2 ϭ 0.7961), our data indicate that neutralizing antibody titers are better predictors for protection than total anti-PA titers and that neutralizing antibody conferred protection regardless of the immunization protocol or the time of challenge.
In order to corroborate the neutralizing antibody hPT 50 , we next studied the protection conferred by passive immunization of rabbits. Various amounts (0.375 to 12 ml/kg) of rabbit anti-PA-based vaccine hyperimmune sera (with a neutralizing antibody titer of 12,800) were administered subcutaneously 48 h before intranasal Vollum spore instillation (10 to 40 LD 50 s). The relationship between neutralizing antibody titers and protection was analyzed (Fig. 4) . Rabbits with neutralizing antibody titers higher than 1,000 resisted challenge, and antibody titers between 500 and 800 conferred protection to 8 of 11 animals (ϳ72.7%), while lower antibody titers did not provide any protection (Fig. 4) . These results suggest that in rabbits neutralizing antibody titers of at least 500 to 800 are necessary for protection against intranasal spore instillation.
DISCUSSION
The correlates between antibody titers and protection against B. anthracis infection in different animal species vaccinated with PA-based vaccines could provide surrogate markers to evaluate the protective efficiency of immunization in humans. In previous studies we determined the immunological correlates for protection of guinea pigs vaccinated with a PA-based vaccine against challenge with Vollum spores injected intradermally (10, 16) . In this study we evaluated the correlates for protection by active immunization of New Zealand White rabbits with a PA-based vaccine or passive immunization of rabbits with anti-PA-based vaccine hyperimmune sera against challenge via intranasal instillation of lethal doses of B. anthracis spores.
Two immunizations that were 4 weeks apart were used to demonstrate the efficacy of AVA (13) or recombinant anthrax vaccine (8) in rabbits against inhalation of B. anthracis Ames spores. In humans, postponement of the second AVA dose (from 2 to 4 weeks after immunization) resulted in an enhanced antibody response (14) . The rabbit model, as presented in this study, supports and corroborates these findings since the same immunization protocol was found (i) to provoke the highest antibody response for either total anti-PA or neutral- (5) or intramuscularly with Ames spores (7) . In addition, PA-neutralizing antibodies were found to represent correlates for protection in guinea pigs (10, 16) . Recently, both neutralizing and IgG anti-PA titers were reported to be correlates for protection in rabbits (8, 13) . In these experiments the rabbits were challenged at week 10 after initiation of immunization. Our data support these findings since at this time the total anti-PA and neutralizing antibody titers were more than 100,000 and 1,000, respectively, in all the rabbits vaccinated. However, as demonstrated by late-challenge experiments, at weeks 19 or 23, our findings indicate that neutralizing antibody titers at the time of challenge should be employed as correlates for immunity in rabbits.
In conclusion, this study completed previous experiments to define correlates for protection induced by an experimental PAbased vaccine. First we defined the antibody titers that provide protection in a guinea pig model challenged by intradermal inoculation (10, 16) , and in the present study we introduced an additional animal model, immunized rabbits challenged via intranasal spore instillation. Both animal models proved that neutralizing antibody titers serve as a reliable surrogate marker for protection against B. anthracis spore challenge.
